A glycosylphosphatidylinositol (GPI)-anchored glycoprotein called the folate receptor 1
(FOLR1) facilitates the transportation of folate by mediating receptor-mediated endocytosis …

Folate receptors are up-regulated on a variety of human cancers, including cancers of the
breast, ovaries, endometrium, lungs, kidneys, colon, brain, and myeloid cells of …

Conventional cancer treatment modalities have several limitations including lack of sufficient
efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In …

Abstract Folate receptor alpha (FOLR1), a glycosylphosphatidylinositol-linked protein, is a
well characterized folate transporter. However, the prognostic power of FOLR1 in cancer …

Folate targeted drug delivery has emerged as an alternative therapy for the treatment and
imaging of many cancers and inflammatory diseases. Due to its small molecular size and …

Folate receptor alpha (FOLR1) has been identified as a potential prognostic and therapeutic
target in a number of cancers. A correlation has been shown between intense …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Over-expression of folate receptor alpha on cancer cells has been frequently exploited for
delivery of folate-targeted imaging and therapeutic agents to tumors. Because limited …

The folate receptor (FR) is a confirmed tumor-associated antigen that binds folate and folate–
drug conjugates with very high affinity and shuttles these bound molecules inside cells via …

Over the last 25+ years, the folate receptor (FR) has emerged as an attractive tumor
biomarker with the potential to be exploited for therapeutic purposes. Increasing evidence …